Russ Conroy

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.